FBN’s Liz MacDonald says Public Citizen is urging the FDA to pull ads for five type-2 diabetes drugs over unapproved claims and off-label marketing.
Rehmann Financial Principal Joe Heider on the health-care stocks to watch.
FBN’s Liz MacDonald with an update on stocks.
Argus Research president John Eade and JPMorgan Funds Chief Global Strategist David Kelly on whether AstraZeneca will re-engage with Pfizer.
Earnings HQ: FBN’s Lori Rothman breaks down Bristol-Myers Squibb ’s first-quarter earnings report.
BGC Partners’ Mike Ingram with the latest on the European markets.
Robert W. Baird & Co. senior analyst Brian Skorney on what investors can expect from pharma in the second quarter.
Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound ($101 billion) takeover approach was rejected, since a deal coul...
Fasten your seat belts. The second quarter is expected to be a bumpy ride.After a volatile first quarter for stocks that ended with the S&P 500 advancing a measly 1....
GlaxoSmithKline Plc (GSK) has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-g...
Novo Nordisk (NYSE:NVO) was handed an upgrade to "buy" from "hold" on Tuesday from Austria's Erste Group, helping to boost its shares 1%.The Denmark-based drug giant...
Bristol-Myers Squibb's (NYSE:BMY) investigational treatment for hepatitis C infection was awarded "breakthrough therapy designation" on Monday by U.S. drug regulator...
AstraZeneca expects earnings to keep falling in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from ...
New York Presbyterian Hospital’s Dr. Mitchell Gaynor on testing the polio virus as a potential cancer treatment.
FBN’s Charles Payne, NewOak Capital President James Frischling, KPMG Chief Economist Constance Hunter, A&G Capital CIO Hilary Kramer and Penn Financial Group founder Matt McCall respond to viewers’ investing questions.
LPL Financial Senior V.P. John Canally, Royal Oak Financial Group Managing Partner Matt Jehn and OptionPit.com founder Mark Sebastian on the outlook for stocks and oil.
Earnings HQ: FBN’s Ashley Webster breaks down Caterpillar’s fourth-quarter earnings report.
Earnings HQ: FBN’s Ashley Webster breaks down Bristol-Myers Squibb ’s fourth-quarter earnings report.
Eli Lilly CEO John Lechleiter discusses new products, 2015 outlook, its Alzheimer’s disease program and animal health division.
Earnings HQ: FBN’s Lori Rothman beaks down Bristol-Myers Squibb ’s third-quarter earnings report.